17.

Assessment of immunity against HBV among children aged 2-17 years in Nnewi, Anambra state

Dr Chukwurah S. N¹, Dr Jisieike-Onuigho N.N¹, Dr Onubogu C.U², Dr Kalu S.O³, Dr Ufoaroh C.U¹, Dr Onah S. K², Dr Ezejiofor O. I¹, Dr Eleje G.U⁴, Dr Mbanuzuru V. A⁵, Dr Okpara H. C⁶, Dr Ezeude C.M¹, Dr Onah CE⁶, Mrs Nweje S. Iˀ, Dr Ekwebene O.C³, Prof Eze KCゥ, Prof Ugochukwu E.F², Prof Ibe C. C⁵.

¹Internal Medicine Department, NAUTH Nnewi

²Paediatrics Department, NAUTH Nnewi

³HIV Care Department, NAUTH Nnewi

⁴Obstetrics and Gynaecology Department, NAUTH Nnewi

⁵Community Medicine Department, NAUTH Nnewi

⁶Chemical Pathology, NAUTH Nnewi

⁷Nursing Department, NAUTH Nnewi

8Medical Officer, NAUTH Nnewi

⁹Radiology Department, NAUTH Nnewi

Correspondence: Dr. Shirley N. Chukwurah Email: nasfic2@gmail.com

Objective: To assess the prevalence of HBsAg, the presence of anti-HBS among vaccinated children aged 2-17 years and the titre levels of anti-HBS among those who have anti-HBS.

Methodology: This was a cross-sectional study of consecutive children aged between 2-17 years seen at the outpatient clinic of NAUTH, Nnewi. Five (5mls) of venous blood was collected from each of the study participants into plain vacutainer tubes and transported to the laboratory for processing. The samples were analyzed for HBV serological markers and anti-HBs titre. Titre of anti-HBs of ≥ 10 IU/L was considered protective while titre less than < 10 IU/L unproductive.

Results: A total of 60 children were used for the study. There was equal male and female distribution (1:1). Most of the respondents (36.7%) were between 10-14 years. 15% of the respondents had their immunity assessed following immunization using panel test. Anti-HBs titre was <10 iu/l in 56.7% of the children and $\ge 10 \text{iu/l}$ in 43.3% of the respondents.

Conclusion: After 18 years of introduction of the HBV vaccine into the National program of immunization and routine infant immunization against hepatitis B virus in Nigeria, it appears that most children are not protected against HBV after completing three doses of the vaccine. A large scale study would be desirable to confirm this finding.

DOI: 10.5281/zenodo.7263421

www.orientjom.com 18